electroCore (NASDAQ:ECOR - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $25.00 price target on the stock. HC Wainwright's price target would suggest a potential upside of 92.31% from the company's current price.
electroCore Trading Down 1.4 %
Shares of NASDAQ ECOR opened at $13.00 on Thursday. The firm has a market cap of $86.53 million, a price-to-earnings ratio of -7.10 and a beta of 0.24. The stock has a fifty day simple moving average of $16.16 and a two-hundred day simple moving average of $12.26. electroCore has a 1-year low of $5.32 and a 1-year high of $19.49.
Institutional Investors Weigh In On electroCore
Several institutional investors have recently added to or reduced their stakes in ECOR. Jane Street Group LLC purchased a new position in shares of electroCore in the fourth quarter worth about $278,000. Marshall Wace LLP purchased a new position in electroCore in the 4th quarter valued at approximately $438,000. NewEdge Advisors LLC purchased a new position in electroCore in the 4th quarter valued at approximately $274,000. Renaissance Technologies LLC raised its holdings in electroCore by 80.6% during the 4th quarter. Renaissance Technologies LLC now owns 131,786 shares of the company's stock valued at $2,136,000 after acquiring an additional 58,800 shares during the period. Finally, DnB Asset Management AS purchased a new stake in shares of electroCore during the fourth quarter worth $180,000. 26.74% of the stock is owned by hedge funds and other institutional investors.
electroCore Company Profile
(
Get Free Report)
electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider electroCore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and electroCore wasn't on the list.
While electroCore currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
